Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer

Immune checkpoint blockade with Programmed cell death 1 (PD-1)/PD-L1 inhibitors has been effective in various malignancies and is considered as a standard treatment modality for patients with non-small-cell lung cancer (NSCLC). However, emerging evidence show that PD-1/PD-L1 blockade can lead to hyp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2019-07, Vol.30 (7), p.1104-1113
Hauptverfasser:	Kim, C.G., Kim, K.H., Pyo, K.-H., Xin, C.-F., Hong, M.H., Ahn, B.-C., Kim, Y., Choi, S.J., Yoon, H.I., Lee, J.G., Lee, C.Y., Park, S.Y., Park, S.-H., Cho, B.C., Shim, H.S., Shin, E.-C., Kim, H.R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents, Immunological - therapeutic use B7-H1 Antigen - antagonists & inhibitors biomarkers Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - immunology Carcinoma, Non-Small-Cell Lung - pathology CD8-Positive T-Lymphocytes - immunology Disease Progression Female Follow-Up Studies Humans hyperprogressive disease Lung Neoplasms - drug therapy Lung Neoplasms - immunology Lung Neoplasms - pathology Lymphatic Metastasis Lymphocytes, Tumor-Infiltrating - immunology Male Middle Aged Neoplasm Metastasis Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - immunology Neoplasm Recurrence, Local - pathology NSCLC PD-1/PD-L1 blockade Prognosis Programmed Cell Death 1 Receptor - antagonists & inhibitors Survival Rate Tumor Burden tumor growth dynamics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!